IBUPROFEN AND FAMOTIDINE
Clinical safety rating: avoid
ACE inhibitors and ARBs may have diminished antihypertensive effect Increases risk of serious cardiovascular thrombotic events and GI bleeding.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever. Famotidine is a histamine H2-receptor antagonist that inhibits gastric acid secretion by blocking histamine at H2 receptors on gastric parietal cells.
| Metabolism | Ibuprofen is primarily metabolized by CYP2C9 and CYP2C8. Famotidine is minimally metabolized in the liver (30-35%) via oxidative pathways; the remainder is excreted unchanged in urine. |
| Excretion | Ibuprofen: Renal excretion of metabolites (90%) and unchanged drug (<10%); biliary/fecal (minor). Famotidine: Renal excretion of unchanged drug (65-70%); metabolites (25-30%); biliary/fecal (minor). |
| Half-life | Ibuprofen: Terminal half-life 2-4 hours (normal renal function); prolonged to 3-6 hours in elderly or hepatic impairment. Famotidine: Terminal half-life 2.5-3.5 hours (normal renal function); extended to >20 hours in severe renal impairment (CrCl <10 mL/min). |
| Protein binding | Ibuprofen: >99% bound to albumin (mostly). Famotidine: 15-20% bound to plasma proteins (albumin). |
| Volume of Distribution | Ibuprofen: 0.1-0.2 L/kg (low, reflects high protein binding and limited tissue distribution). Famotidine: 1.1-1.4 L/kg (suggests extensive extravascular distribution). |
| Bioavailability | Ibuprofen: Oral: 80-100% (well absorbed with food causing slight delay). Famotidine: Oral: 40-50% (first-pass metabolism; reduced with food). |
| Onset of Action | Ibuprofen: Oral immediate-release: 30-60 minutes (analgesic/anorectic effect). Famotidine: Oral: 1 hour (acid suppression); maximum effect at 1-3 hours. |
| Duration of Action | Ibuprofen: 4-6 hours (analgesic effect); longer with extended-release formulations. Famotidine: Acid suppression lasts 10-12 hours (dose-dependent). |
| Molecular Weight | Ibuprofen: 206.28 Da; Famotidine: 337.45 Da |
One tablet (ibuprofen 800 mg/famotidine 26.6 mg) orally three times daily.
| Dosage form | TABLET |
| Renal impairment | Contraindicated if CrCl < 30 mL/min. For CrCl 30-49 mL/min, reduce famotidine dose by 50% (not possible with fixed combination; use alternative therapy). |
| Liver impairment | No specific dose adjustment for Child-Pugh A or B; avoid in severe hepatic impairment (Child-Pugh C) due to ibuprofen component. |
| Pediatric use | Not established for combination; ibuprofen 5-10 mg/kg/dose (max 400 mg) q6-8h as separate agent; famotidine 0.5 mg/kg/dose (max 20 mg) q12h for pediatric use. |
| Geriatric use | Start at lowest effective dose; monitor renal function; avoid if CrCl < 30 mL/min; increased risk of GI bleeding and renal impairment. |
| 1st trimester | Ibuprofen is generally avoided in the first trimester due to potential increased risk of spontaneous abortion and congenital malformations; famotidine is considered safe (Category B). |
| 2nd trimester | Ibuprofen is relatively safer in the second trimester but should be used at lowest effective dose for shortest duration; famotidine is considered safe. |
| 3rd trimester | Ibuprofen is contraindicated after 30 weeks gestation due to risk of premature closure of ductus arteriosus and oligohydramnios; famotidine is considered safe (Category B). |
Clinical note
ACE inhibitors and ARBs may have diminished antihypertensive effect Increases risk of serious cardiovascular thrombotic events and GI bleeding.
| FDA category | Positive |
| Placental transfer | Ibuprofen crosses the placenta; fetal concentrations may reach up to 50% of maternal levels. Famotidine crosses the placenta in limited amounts. |
■ FDA Black Box Warning
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. NSAIDs are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.
| Common Effects | fever |
| Serious Effects |
Hypersensitivity to ibuprofen, famotidine, or any component of the formulationHistory of allergic-type reactions to aspirin or other NSAIDsActive or history of peptic ulcer disease or gastrointestinal bleedingSevere renal impairment (CrCl <30 mL/min)Third trimester of pregnancy (after 30 weeks gestation)Perioperative pain in the setting of coronary artery bypass graft (CABG) surgery
| Precautions | Cardiovascular risk: Increased risk of serious cardiovascular thrombotic events. Gastrointestinal risk: Serious GI adverse events including bleeding, ulceration, and perforation. Renal toxicity: Monitor renal function. Hepatic effects: Elevation of liver enzymes. Anaphylactoid reactions: Bronchospasm in aspirin-sensitive asthma. Hypertension: Can worsen blood pressure control. Fluid retention and edema. |
Loading safety data…
| Breastfeeding | Ibuprofen is excreted into breast milk in very low concentrations and is considered compatible with breastfeeding when used at recommended doses. Famotidine is excreted into breast milk but in amounts that are not expected to cause adverse effects in the infant. Both are generally considered safe during breastfeeding, but caution is advised with prolonged high doses. |
| Lactation Rating | L2 (Safer) - Ibuprofen and famotidine individually are rated L2. |
| Teratogenic Risk | First trimester: Ibuprofen is associated with increased risk of miscarriage and congenital malformations (cardiac defects, gastroschisis). Famotidine is generally considered low risk, but limited data. Second trimester: Ibuprofen use is linked to fetal renal dysfunction and oligohydramnios; famotidine appears safe. Third trimester: Ibuprofen is contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal pulmonary hypertension; famotidine has no known fetal risks. |
| Fetal Monitoring | Maternal: Renal function, blood pressure, signs of gastrointestinal bleeding. Fetal: Ultrasound for oligohydramnios and ductus arteriosus patency if ibuprofen used in second/third trimester; growth monitoring. |
| Fertility Effects | Ibuprofen may reversibly impair female fertility by affecting ovulation (prostaglandin inhibition); effects resolve upon discontinuation. Famotidine has no known impact on fertility. |
| Food/Dietary | Avoid alcohol; increases GI bleeding risk. No other significant food interactions. Take with food or milk to reduce gastric irritation. |
| Clinical Pearls | Ibuprofen and famotidine combination tablet (Duexis) is used for osteoarthritis and rheumatoid arthritis to reduce GI ulcer risk. Do not exceed 800 mg ibuprofen per dose or 3200 mg per day. Famotidine component provides gastric protection; additional acid suppression not needed. Avoid in advanced renal disease, active GI bleeding, or COX-2 inhibitor allergy. Monitor renal function, BP, and signs of GI bleeding. Dual COX/5-LOX inhibition by ibuprofen raises cardiovascular thrombotic risk; use lowest effective dose. |
| Patient Advice | Take with food or milk to reduce stomach upset. · Do not take more than 3 tablets per day (each tablet contains 800 mg ibuprofen). · May cause drowsiness or dizziness; avoid driving if affected. · Report black/tarry stools, vomiting blood, chest pain, or leg swelling immediately. · Avoid alcohol and other NSAIDs (e.g., aspirin, naproxen) while taking this medication. · Inform all healthcare providers you are taking this drug, especially before surgery. |